Gimenez: China lockdowns severely disrupted biotech startup supply chains
Dr. Francisco Gimenez · The Year That Changed Medicine Forever | Francisco Gimenez Explains the Biotech Revolution. · Joe Lonsdale · Apr 18, 2022 · at 31:55
Dr. Francisco Gimenez, partner at 8VC, explains how foreign reliance on contract research organizations (CROs) and reagents exposed vulnerabilities in the U.S. biotech ecosystem.
0:00 / 0:13exact quote · 13.9s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“When Wuhan shut down and basically all of China shut down, it wasn't just medicines, but it was entire sort of our biotech supply chain. So many of our companies had huge delays in the sort of reagents they were able to get deals, they were able to close or whatever, because there's so many CROs out there.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Francisco Gimenez
Gimenez: More biotechs will commercialize drugs independently instead of selling
“I would say my sort of falsifiable prediction would be that we're going to start seeing more and more biotechs make drugs that they try to commercialize themselves as opposed to selling to pharma to do the commercialization.”
Gimenez: Rare cancer therapies build infrastructure to cure broader diseases
“Once we create the tools and technologies to cure those,
We have this infrastructure layer that allows us to expand it to so many others. So we cure rare cancers or cell therapies today, but we're looking and building all of the infrastructure, the manufactur…”
Gimenez: Eliminating Startup Upside Would Entrench Incumbent Pharma
“If we didn't give people upside to translate these things, there would not be a system to actually sort of commercialize these things in a sort of fast turnaround biotech ecosystem. We would be dependent, it's not like that, that innovation would go away, but …”
Gimenez: Just 100 to 200 pharma CSOs dictate which diseases get cured
“So we've got, like, on the order of, what, a hundred, maybe 200 pharmas looking to make these M&As. So it means a hundred to 200 chief scientific officers are dictating what does.”
Gimenez: Tenured academics enjoy the privilege of principle without practical trade-offs
“If you are in a tenured position in academia and you consider moving to industry, the dark side, which is always considered like the phrase that they tell you have like the privilege of principle that many other people don't, right? You don't have to make trad…”
Gimenez: Life sciences will shift from curing diseases to active human enhancement
“I think we would flip the model of what we think of in bio life sciences from amelioration of suffering, which is essentially curing diseases, to sort of improvement of, like, human condition, like this, the transhumanist might call it something like that”